{
    "id": 21012,
    "cites": 59,
    "cited_by": 16,
    "reference": [
        "Acemoglu, D. and J. Linn (2004). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119: 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090.",
        "Anderson, S. P. and R. Renault. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Efficiency and Surplus Bounds in Cournot Competition,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Theory 113: 253\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c264.",
        "Anderson, O. W., P. Collette, and J. J. Feldman. (1960) Expenditure Patterns for Personal Health Services, 1953 and 1958: Nationwide Survey. New York: Health Information Foundation.",
        "Baumol, W. J., J. C. Panzar, and R. D. Willig. (1982) Contestable Markets and the Theory of Industry Structure. New York: Harcourt Brace Jovanovich.",
        "Bergemann, D., B. Brooks, and S. Morris. (2014) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Limits of Price Discrimination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cowles Foundation working paper no. 1896RR.",
        "Biehl, A. R. (2001) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Durable-Goods Monopoly with Stochastic Values,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Rand Journal of Economics 32: 565\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c577.",
        "Blanchflower, D. G. and A. J. Oswald. (2004) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Well-Being Over Time in Britain and the USA,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 88: 1359\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1386.",
        "Boulier, B. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Shot in the Dark: Uncertainty and Vaccine Demand and Supply,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d George Washington University working paper.",
        "Brito, D. L., E. Sheshinski, and M. D. Intrilligator. (1991) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Externalities and Compulsory Vaccination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 45: 69\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c90. Brooks, B. A. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Surveying and Selling: Belief and Surplus Extraction in Auctions,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Princeton University working paper.",
        "Budish, E., B. N. Roin, and H. Williams. (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research working paper no. 19430.",
        "Bulow, J. I., J. D. Geanakoplos, and P. D. Klemperer. (1985) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Multimarket Oligopoly: Strategic Substitutes and Complements,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 93: 488\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c511.",
        "Centers for Disease Control. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data, United States and 6 Dependent Areas, 2010,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d HIV Surveillance Supplemental Report vol. 17, no. 3.",
        "Clay, K. B., D. S. Sibley, and P. Srinagesh. (1992) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ex Post vs. Ex Ante Pricing: Optional Calling Plans and Tapered Tariffs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Regulatory Economics 4: 115\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c138.",
        "Courty, P. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ticket Pricing Under Demand Uncertainty,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 46: 627\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 652.",
        "De Graba, P. (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Buying Frenzies and Seller-Induced Excess Demand,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Rand Journal of Economics 26: 331-342.",
        "Euerle, B. and P. H. Chandrasekar. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Syphilis,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in B. A. Cunha, ed., Medscape Reference. Accessed August 27, 2012 from emedicine.medscape.com/article/229461.",
        "Fabinger, M. and E. G. Weyl. (2014) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Tractable Approach to Pass-Through Patterns with Applications to International Trade,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d SSRN working paper, available at http://ssrn.com/abstract=2194855.",
        "Francis, P. J. (1997) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Dynamic Epidemiology and the Market for Vaccinations,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 63: 383-406.",
        "Finkelstein, A. (2004). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and Dynamic Effect of Health Policy: Evidence from the Vaccine Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119: 527\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c564.",
        "Gabaix, X. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Power Laws in Economics and Finance,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Annual Review of Economics 1: 255\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c293.",
        "Garber, A. M., C. I. Jones, and P. Romer. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurance and Incentives for Medical Innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy 9: 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c27.",
        "Geoffard, P.-Y. and T. Philipson. (1997) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Disease Eradication: Public vs. Private Vaccination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 87: 222-230.",
        "Gersovitz, M. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Births, Recoveries, Vaccinations, and Externalities,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in R. Arnott, ed., Economics for an Imperfect World: Essays in Honor of Joseph E. Stiglitz, 469\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c483.",
        "Gersovitz, M. and J. S. Hammer. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Tax/Subsidy Policy Toward Vector-Borne Infectious Diseases,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 89: 647\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c674.",
        "Getzen, T. E. (2000) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health care is an Individual Necessity and a National Luxury: Applying Multilevel Decision Models to the Analysis of Health Care Expenditures,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 19: 259\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c270.",
        "Harpavat, S. and S. Nissim. (2001) MicroCards: Review Cards for Medical Students. Philadelphia: Lippincott Williams & Wilkins.",
        "Hartline, J. D. and T. Roughgarden. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Simple Versus Optimal Mechanisms,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Proceedings of the 10th ACM Conference on Electronic Commerce 225\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c234.",
        "Hernandez, B. Y., et al. (2008) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Transmission of Human Papillomavirus in Heterosexual Couples,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Emerging Infectious Diseases 14: 888\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c894.",
        "Howard, Robin S. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Poliomyelitis and the Postpolio Syndrome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d British Medical Journal 330: 1314\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 1318.",
        "Kaplan, E. H. (1990) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Modeling HIV Infectivity: Must Sex Acts Be Counted?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Acquired Immune Deficiency Syndromes 3: 55\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c61.",
        "Kessing, S. G. and R. Nuscheler. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Monopoly Pricing with Negative Network Effects: The Case of Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d European Economic Review 50: 1061\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1069.",
        "Klein, B., R. A. Crawford, and A. A. Alchian. (1978) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vertical Integration, Appropriable Rents, and the Competitive Contracting Process,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 21: 297\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c326.",
        "Kremer, M. and R. Glennerster. (2004) Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton: Princeton University Press.",
        "Kremer, M. and C. M. Snyder. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why Are Drugs More Profitable Than Vaccines?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research working paper no. 9833.",
        "Kremer, M. and C. M. Snyder. (2015) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Worst-Case Bounds on R&D and Pricing Distortions: Theory and Disturbing Conclusions if Consumer Values Follow the World Income Distribution,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Harvard University.",
        "Kremer, M., C. M. Snyder, and H. Williams. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccines: Integrated Economic and Epidemiological Models,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Harvard University.",
        "Lakdawalla, D. and N. Sood. (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Insurance as a Two-Part Pricing Contract,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 102: 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c12.",
        "Lau, Brandyn D., Brian L. Pinto, David R. Thiemann, and Christoph U. Lehmann. (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Budget Impact Analysis of Conversion from Intravenous to Oral Medication When Clinically Eligible for Oral Intake,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Therapeutics 33: 1792\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1796.",
        "Lewis, T. R. and D. E. M. Sappington. (1994) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Supplying Information to Facilitate Price Discrimination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Economic Review 35: 309\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c327.",
        "Makowski, L. and J. M. Ostroy. (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Appropriation and Efficiency: A Revision of the First Theorem of Welfare Economics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 85: 808\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c827.",
        "Maleug, D. A. and C. M. Snyder (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Bounding the Relative Profitability of Price Discrimination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Industrial Organization 24: 995-1011.",
        "Mandell, G. L., J. E. Bennett, and R. Dolin. (2009) Principles and Practice of Infectious Diseases seventh edition. Philadelphia: Elsevier Churchill Livingstone.",
        "McNeil, D. G. (2014) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Advocating Pill, U.S. Signals Shift to Prevent AIDS,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Times May 15, A1.",
        "Miravete, E. (1996) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Screening Consumers Through Alternative Pricing Mechanisms,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Regulatory Economics 9: 111\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c132.",
        "Morbidity and Mortality Weekly Report. (various years) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Summary of Notifiable Diseases, United States,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Centers for Disease Control and Prevention, downloaded December 20, 2009 from www.cdc.gov/-mmwr/mmwr_nd/index.html Mueller, Steffen, Eckard Wimmer, and Jeronimo Cello. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Poliovirus and Poliomyelitis: A Tale of Guts, Brains, and an Accidental Event,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Virus Research 111: 175\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c193.",
        "National Cancer Institute. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093BRCA1 and BRCA2: Cancer Risk and Genetic Testing,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Cancer Institute Fact Sheet. Retrieved August 16, 2012, from www.cancer.gov/cancertopics/factsheet/-Risk/BRCA.",
        "Newell, R., A. Jaffee, and R. N. Stavins. (1999) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Induced Innovation Hypothesis and Energy-Saving Technological Change,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 114: 907\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c940.",
        "Oster, E. (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Unobservable Selection and Coefficient Stability: Theory and Evidence,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER working paper no. 19054.",
        "Purcell, D. W., et al. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the Population Size of Men Who Have Sex with Men in the United States to Obtain HIV and Syphillis Rates,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Open AIDS Journal 6: 98\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c107.",
        "Rockstroh, J. K., et al. (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Male-to-Female Transmission of HIV in a Cohort of Hemophiliacs\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d Frequency, Risk Factors and Effect of Sexual Counseling,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Infection 23: 29\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c32.",
        "Rosenberg, E. (1999) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Makers Shy from Work on AIDS Vaccine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d San Francisco Examiner. March 16.",
        "Snyder, C. M., W. Begor, and E. R. Berndt. (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Economic Perspectives on the Advance Market Commitment for Pneumococcal Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 30: 1508\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1517.",
        "Thomas, P. (2002) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Economics of Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Medical International (HMI) World. September /October.",
        "Tirole, J. (1988) The Theory of Industrial Organization. Cambridge, Massachusetts: MIT Press.",
        "U.S. Census Bureau. (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vintage 2007: National Tables: National Characteristics: National Sex, Race, and Hispanic Origin,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded September 16, 2013 from www.census.gov/popest/data/-historical/2000s/vintage_2007/index.html.",
        "Weyl, E. G. and M. Fabinger. (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pass-Through as an Economic Tool: Principles of Incidence under Imperfect Competition,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 121: 528\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c583.",
        "Weyl, E. G. and J. Tirole. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Power Screens Willingness-to-Pay,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 127: 1971\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2003.",
        "We are set to apply the decomposition results from Section 3.2. Substituting the definition \u00c3\u008f\u00c2\u0081\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0094 X = RECX /X into the decomposition formula in (10) gives RECX /X = 1\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099ZX [1\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099\u00c3\u008f\u00c2\u0081(X )]. Similarly, REC \u00c3\u008b\u00c5\u0093 H/ \u00c3\u008b\u00c5\u0093 H = 1\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099Z \u00c3\u008b\u00c5\u0093 H[1\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099\u00c3\u008f\u00c2\u0081( \u00c3\u008b\u00c5\u0093 H)]. Substituting, we have that \u00c3\u008f\u00c2\u0081( \u00c3\u008b\u00c5\u0093 H)/Z \u00c3\u008b\u00c5\u0093 H > REC(X )/ZX > RECX /X if and only if ZX [1\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099 \u00c3\u008f\u00c2\u0081(X )] > Z \u00c3\u008b\u00c5\u0093 H[1 \u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099 \u00c3\u008f\u00c2\u0081( \u00c3\u008b\u00c5\u0093 H)], which is thus a necessary and sufficient condition for PSo t > PSo p. The reverse inequalities are proved similarly. Q.E.D. Online appendix Online Appendix C: Computing \u00c3\u008e\u00c2\u00b2 in Calibrations of the Kaplan Model This online appendix provides details on the derivation of \u00c3\u008e\u00c2\u00b2 used in the calibrations based on the Kaplan (1990) model.",
        "HIV2 Calibration: Calibration HIV2 assumes a homogeneous \u00c3\u008e\u00c2\u00b2 parameter across the U.S. population, computed by multiplying an estimate of the per-partner transmission rate by an estimate of the HIV prevalence rate. We take the per-partner transmission rate to be 10% from Rockstroh et al. (1995). The overall prevalence rate is computed from subgroup estimates in Purcell et al. (2012), a meta-analysis of seven surveys covering the 37 states with confidential, name-based HIV infection reporting. The following table reproduces estimates from their Table 5 of the number of HIV cases [in column (1)] and rates [in column (2)] by year end 2007 for the three mutually exclusive subgroups in the row headings."
    ]
}